Summit Therapeutics Inc. 8-K

What Happened

• Summit Therapeutics Inc. held its 2026 Annual Meeting of Stockholders on June 10, 2026 and filed an 8-K on June 12, 2026 reporting the results. All nine director nominees were elected to serve until the 2027 annual meeting. PricewaterhouseCoopers LLP was ratified as the company’s independent registered public accounting firm for fiscal 2026. A non‑binding advisory vote to approve executive compensation passed, and shareholders approved an amendment to the Summit Therapeutics Inc. 2020 Stock Incentive Plan to add 8,000,000 shares.

Key Details

• Director elections (For / Withheld; broker non‑votes 30,576,341 for each nominee):
  • Robert W. Duggan: 636,409,964 For; 10,761,538 Withheld
  • Mahkam Zanganeh: 637,405,433 For; 9,766,069 Withheld
  • Manmeet Soni: 636,690,652 For; 10,480,850 Withheld
  • Kenneth A. Clark: 622,127,920 For; 25,043,582 Withheld
  • Robert Booth: 646,257,923 For; 913,579 Withheld
  • Alessandra Cesano: 646,263,718 For; 907,784 Withheld
  • Yu (Michelle) Xia: 636,028,876 For; 11,142,626 Withheld
  • Mostafa Ronaghi: 646,570,238 For; 601,264 Withheld
  • Jeff Huber: 646,659,701 For; 511,801 Withheld
• Auditor ratification (Proposal 2): PwC ratified — 677,302,337 For; 85,284 Against; 360,222 Abstain.
• Advisory vote on executive compensation (Proposal 3): Passed — 622,624,328 For; 24,445,791 Against; 101,383 Abstain (broker non‑votes 30,576,341).
• Stock Incentive Plan amendment (Proposal 4): Approved — increase of 8,000,000 shares; vote 619,799,393 For; 27,247,910 Against; 124,199 Abstain (broker non‑votes 30,576,341).

Why It Matters

• The votes keep the current board and auditor in place, which means continuity in governance and financial oversight for the coming year.
• The non‑binding “say‑on‑pay” approval indicates majority shareholder support for executive compensation as presented, but it is advisory and not legally binding.
• Approval of an additional 8,000,000 shares under the 2020 Stock Incentive Plan increases the pool available for equity awards to executives, employees or directors — a potential source of future dilution if and when shares are issued.
• These are procedural, governance and capital‑structure items that affect shareholder rights and the company’s ability to grant equity incentives; they do not report operating results or financial performance.